Institute for Infectiology, University of Münster, Münster, Germany.
German Center for Infection Research (DZIF), Associated Site University of Münster, Münster, Germany.
Front Cell Infect Microbiol. 2020 May 6;10:169. doi: 10.3389/fcimb.2020.00169. eCollection 2020.
Infections with Shiga toxin-producing (STEC) cause outbreaks of severe diarrheal disease in children and the elderly around the world. The severe complications associated with toxin production and release range from bloody diarrhea and hemorrhagic colitis to hemolytic-uremic syndrome, kidney failure, and neurological issues. As the use of antibiotics for treatment of the infection has long been controversial due to reports that antibiotics may increase the production of Shiga toxin, the recommended therapy today is mainly supportive. In recent years, a variety of alternative treatment approaches such as monoclonal antibodies or antisera directed against Shiga toxin, toxin receptor analogs, and several vaccination strategies have been developed and evaluated and in animal models. A few strategies have progressed to the clinical trial phase. Here, we review the current understanding of and the progress made in the development of treatment options against STEC infections and discuss their potential.
产志贺毒素（STEC）的感染会导致全球儿童和老年人爆发严重的腹泻病。与毒素产生和释放相关的严重并发症范围从血性腹泻和出血性结肠炎到溶血性尿毒综合征、肾衰竭和神经系统问题。由于抗生素治疗感染的使用一直存在争议，因为有报道称抗生素可能会增加志贺毒素的产生，因此目前的推荐治疗主要是支持性的。近年来，已经开发和评估了多种替代治疗方法，如针对志贺毒素的单克隆抗体或抗血清、毒素受体类似物和几种疫苗接种策略，并在动物模型中进行了评估。一些策略已经进入临床试验阶段。在这里，我们回顾了针对 STEC 感染的治疗选择的现有认识和进展，并讨论了它们的潜力。
